 |
 |
|
 |
||
 |
 |
|
 |
|
|
| Daniel Clarke-Pearson, M.D.
Professor, Chair |  |
Research Interests
1. Prevention and diagnosis of Venous Thromboembolism following gynecologic oncology surgery
2. Gyn Oncology clinical trials.
Recent Accomplishments and Honors
979 Junior Fellow First Prize Paper - ACOG District IV
1980 American Cancer Society Clinical Fellow
1981 Junior Fellow First Prize Paper - ACOG District IV
1981 Clinical Research Paper, Second Place
ACOG Annual Clinical Meeting
1982 Donald F. Richardson Memorial Prize Paper
Best research paper presented by a Junior Fellow at a District
ACOG Meeting
1981-1984 Junior Faculty Clinical Fellowship - American Cancer Society
1985 Clinical Research Prize Paper - ACOG District VI Meeting
1991 Invited Panel Participant
Consensus Meeting on the Prevention of Thromboembolism
Windsor, England
2001 Americas Top Doctors
2002 ACOG Roy Pitkin/Elsevier Award: One of top four papers published annually in Obstetrics and Gynecology
2004 Invited Panel Member, International Consensus Conference of the Prevention of Venous Thromboembolism
Training
Undergraduate:
Sept 1966 - Harvard College June, 1970 B.A. (Biology)
Cambridge, Massachusetts
Graduate:
Sept 1971 - Case Western Reserve May, 1975 M.D.
May 1975 University School of Medicine
Cleveland, Ohio
Postgraduate
July 1975 - Assistant Resident, Obstetrics and Gynecology
June 1978 Duke University Medical Center, Durham, North Carolina
Roy T. Parker, M.D.
Chairman
July 1978 - Chief Resident, Obstetrics and Gynecology
June 1979 Duke University Medical Center, Durham, North Carolina
Roy T. Parker, M.D.
Chairman
July 1979 - Fellow, Gynecologic Oncology
June 1981 Duke University Medical Center, Durham, North Carolina
William T. Creasman, M.D.
Program Director
Books:
1. Clarke-Pearson DL: Handbook for Residents: Gynecologic Oncology. University of Illinois Press (95 Pages), 1986.
2. Clarke-Pearson DL, Dawood MY: Green's Gynecology: Essentials of Clinical Practice, Fourth Edition. Little, Brown and Company, Boston, 1990.
3. Clarke-Pearson DL, Soper JT, Berchuck A, Rodriguez GC: Residents Handbook in Gynecologic Oncology, Duke University, 1988, 1994.
4. Nichols D, Clarke-Pearson DL: Gynecologic, Obstetric and Related Surgery: Second Edition. Mosby, St. Louis, 2000.
Publications
Refereed Journals:
1. Wheeler HB, Mullick SC, Anderson JM, Pearson DL: Diagnosis of occult deep vein thrombosis by a noninvasive bedside technique. Surg 70:20, 1971.
2. Wheeler HB, Pearson DL, O'Connell D, Mullick SC: Impedance phlebography: Technique, interpretation, and results. Arch Surg 104:164, 1972.
3. Clarke-Pearson DL: The importance of calf vein thrombosis. N Eng J Med 302:752, 1980.
4. Clarke-Pearson DL: Low-dose heparin in prevention of deep venous thrombosis. Am J Obstet Gynecol 138:471, 1980.
5. Clarke-Pearson DL, Jelovsek FR: Alterations of occlusive cuff impedance plethysmography results in the obstetric patient. Surg 89:594, 1981.
6. Creasman WT, Clarke-Pearson DL, Ashe CA, Weed JC Jr: The abnormal pap smear: What to do next. Cancer 48:515, 1981.
7. Clarke-Pearson DL, Creasman WT: Diagnosis of deep venous thrombosis in obstetrics and gynecology by impedance phlebography. Obstet Gynecol 58:52, 1981.
8. Creasman WT, Clarke-Pearson DL, Weed JC, Jr: Results of outpatient therapy of cervical intraepithelial neoplasia. Gynecol Oncol 12:306-316, 1981.
9. Clarke-Pearson DL, Synan IS, Creasman WT: Significant venous thromboembolism caused by pelvic lymphocysts: Diagnosis and management. Gynecol Oncol 13:136, 1982.
10. Clarke-Pearson DL, Coleman RE, Ralston M, Creasman WT: Indium-labeled platelet imaging of postoperative pelvic vein thrombi. Obstet Gynecol 62:109-116, 1983.
11. Clarke-Pearson DL, Jelovsek FR, Creasman WT: Thromboembolism complicating surgery for cervical and uterine malignancy: Incidence, risk factors and prophylaxis. Obstet Gynecol 61:87-94, 1983.
12. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT: Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 145:606-613, 1983.
13. Clarke-Pearson DL, Synan IS, Creasman WT: Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol 147:369-375, 1983.
14. Bandy L, Clarke-Pearson DL, Creasman WT: Vitamin B12 deficiency following therapy in gynecologic oncology. Gynecol Oncol 17:370-374, 1984.
15. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM: Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecology: Report of a randomized controlled trial. Gynecol Oncol 18:226-232, 1984.
16. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT: Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 63:92-98, 1984.
17. Creasman WT, Hinshaw WM, Clarke-Pearson DL: Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol 63:145-149, 1984.
18. Clarke-Pearson DL, Synan IS, Coleman RE, Hinshaw WM, Creasman WT: The natural history of venous thromboemboli in gynecologic oncology: A prospective study of 382 patients. Am J Obstet Gynecol 148:1051, 1984.
19. Gore M, Miller KE, Soong S, Clarke-Pearson DL, Pizzo SV: Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. Am J Obstet Gynecol 149:830-834, 1984.
20. Clarke-Pearson DL, Coleman RE, Petry N, Synan IS, Creasman WT: Postoperative pelvic vein thrombosis and pulmonary embolism detected by indium 111-labeled platelet imaging: A case report. Am J Obstet Gynecol 149:796-798, 1984.
21. Soper JT, McCarty KS Jr, Hinshaw WM, Creasman WT, McCarty KS Sr, Clarke-Pearson DL: Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 150:342-348, 1984.
22. Bandy L, Clarke-Pearson DL, Hammond CB: Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 64:395-399, 1984.
23. Clarke-Pearson DL, DeLong ER, Synan IS, Creasman WT: Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol 64:689-694, 1984.
24. Smith EB, Clarke-Pearson DL, Creasman WT: A VP-16-213 and cisplatin containing regimen for treatment of refractory ovarian germ cell malignancies. Am J Obstet Gynecol 150:927-931, 1984.
25. Soper JT, McCarty KS Jr, Creasman WT, Clarke-Pearson DL, McCarty KS Sr: Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gynecol 150:437, 1984.
26. Zern RA, Clarke-Pearson DL: Pneumatosis intestinalis associated with enteral feeding by catheter jejunostomy. Obstet Gynecol 65:81S-83, 1985.
27. Fortier KJ, Clarke-Pearson DL, Creasman WT, Johnston WW: Fine Needle Aspiration in Gynecology: Evaluation of extra pelvic lesions in patients with gynecologic malignancy. Obstet Gynecol 65:76-72, 1985.
28. Bandy L, Clarke-Pearson DL, Silverman PM, Creasman WT: Computed tomography in evaluation of extra pelvic lymphadenopathy in carcinoma of the cervix. Obstet Gynecol 65:73-76, 1985.
29. Clarke-Pearson DL, Creasman WT: A clinical evaluation of absorbable polydioxanone ligating clips in abdominal and pelvic operations. Surg Gynecol Obstet 161:250-252, 1985.
30. Bandy L, Clarke-Pearson DL, Hammond CB: Pseudoobstruction of the colon complicating choriocarcinoma. Gynecol Oncol 20:402-407, 1985.
31. Clarke-Pearson DL, Coleman RE, Siegel R, Synan IS, Petry N: Indium 111 platelet imaging for the detection of deep venous thrombosis and pulmonary embolism in patients without symptoms after surgery. Surg 98:98-103, 1985.
32. Barter JF, Smith EB, Szpak CA, Hinshaw WM, Clarke-Pearson DL, Creasman WT: Leiomyosarcoma of the uterus: Clinicopathologic study of 21 cases. Gynecol Oncol 21:220-227, 1985.
33. Creasman WT, Fetter BF, Clarke-Pearson DL, Kaufman L, Parker RT: Management of Stage IA carcinoma of the cervix. Am J Obstet Gynecol 153:164-171, 1985.
34. Soper JT, Creasman WT, Clarke-Pearson DL, Sullivan DC, Vergadoro F, Johnston WW: Intraperitoneal chromic phosphate P32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 153:191-196, 1985.
35. Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw WM, Clarke-Pearson DL: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151:7, 922-932, 1985.
36. Puleo J, Clarke-Pearson D, Smith E, Barnard D, Creasman W: Superior vena cava syndrome associated with gynecologic malignancy. Gynec Onc 23:59-64, 1986.
37. Creasman WT, Henderson D, Clarke-Pearson DL, Hinshaw WM: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67:326-330, 1986.
38. Mutch DG, Soper JT, Baker ME, Bandy L, Cox EB, Clarke-Pearson DL, Hammond CB: The role of computerized axial tomography of the chest in staging patients with nonmetastatic gestational trophoblastic disease. Obstet Gynecol 68:348-352, 1986.
39. Clarke-Pearson DL, Bandy L, Dudzinski M, Heaston D, Creasman WT: Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission: correlation with surgical pathologic findings. JAMA 255:627-630, 1986.
40. Creasman WT, Soper JT, Clarke-Pearson DL: Radical hysterectomy as therapy for early carcinoma of the cervix. Am J Obstet Gynecol 155:964-969, 1986.
41. Clarke-Pearson DL, Chin N, DeLong ER, Rice R, Creasman WT: Surgical management of intestinal obstruction in ovarian cancer: I. Clinical features, postoperative complication, and survival. Gynecol Oncol 26:11-18, 1987.
42. Clarke-Pearson DL, DeLong ER, Synan IS, Coleman RE, Creasman WT: Variables associated with postoperative deep venous thrombosis: A prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol 69:146-150, 1987.
43. Soper JT, Wilkinson RH, Bandy LC, Clarke-Pearson DL, Creasman WT: Intraperitoneal chromic phosphate P32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol 156:1153, 1987.
44. Beckmann CRB, Clarke-Pearson DL, Evenhouse R: A reusable plastic training model for teaching Papanicolaou smear technique. Am J Obstet Gynecol 157:259-260, 1987.
45. Bandy LC, Clarke-Pearson DL, Soper JT, Mutch DG, MacMillan J, Creasman WT: Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecol 26:160, 1987.
46. Clarke-Pearson DL, DeLong ER, Chin N, Rice R, Creasman WT: Intestinal obstruction in patients with ovarian cancer: Variables associated with surgical complications and survival. Arch Surg 123:42-45, 1988.
47. Soper JT, Clarke-Pearson DL, Hammond CB: Metastatic gestational trophoblastic disease: Prognostic factors in previously untreated patients. Obstet Gynecol 71:338-343, 1988.
48. Soper JT, Clarke-Pearson DL, Creasman WT: Absorbable synthetic mesh (910-polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. Gynecol Oncol 29:283-289, 1988.
49. Clarke-Pearson DL, Soper JT, Creasman WT: Absorbable synthetic mesh (910-polyglactin) for creation of a pelvic "lid" following pelvic exenteration. Am J Obstet Gynecol 158:158-160, 1988.
50. Soper JT, Mutch DG, Chin N, Clarke-Pearson DL, Hammond CB: Renal metastases of gestational trophoblastic disease: A report of eight cases. Obstet Gynecol 72:797-798, 1988.
51. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988.
52. Soper JT, Blaszcyk TM, Oke TZ, Clarke-Pearson DL, Creasman WT: Percutaneous nephrostomy in gynecologic oncology patients. Am J Obstet Gynecol 158:1126-1131, 1988.
53. Clarke-Pearson DL, DeLong ER, Chin N, Rice R, Creasman WT: Intestinal obstruction in patients with ovarian cancer: variables associated with surgical complications and survival. Arch Surg 123:42-45, 1988.
54. Clarke-Pearson DL, Olt G: Thromboembolism in patients with gynecologic tumors: Risk factors, natural history and prophylaxis. Oncol 3:39-44, 1989.
55. Clarke-Pearson DL, Hume RF: Venous thromboembolic disease in Obstetrics and Gynecology: Prevention, diagnosis and treatment. Curr Probl Obstet Gynecol Fertil 12:38-63, 1989.
56. Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RT, McCarty KS, Bast RC: Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: Correlation of antigen expression with metastatic potential. Cancer Res 49:2091-2095, 1989.
57. Soper JT, Berchuck A, Creasman WT, Clarke-Pearson DL: Pelvic exenteration: Factors associated with major surgical morbidity. Gynecol Oncol 35:93-98, 1989.
58. Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Bast RC Jr, McCarty KS Jr: Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. Arch Pathol Lab Med 113:1155-1158, 1989.
59. Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS Jr, Bast RC Jr: Immunohistochemical expression of Tag-72 in normal and malignant endometrium: Correlation of antigen expression with estrogen receptor and progesterone receptor levels. Am J Obstet Gynecol 161:1258-1263, 1989.
60. Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC Jr, McCarty KS Jr: Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 161:1247-1252, 1989.
61. Soper JT, Larson D, Hunter VJ, Berchuck A, Clarke-Pearson DL. Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery. Obstet Gynecol 74:823-827, 1989.
62. Fu SF, Clarke-Pearson DL: Complications of intraperitoneal port-a-cath for treatment of ovarian carcinoma. Taiwan Med J 32:521-526, 1989.
63. King ME, DiGiovanni LM, Yong FF, Clarke-Pearson DL: Immature teratoma of the ovary, Grade 3, with karyotype analysis. Int J Gynecol Pathol 9:178-184, 1990.
64. Bentel GC, Oleson JR, Clarke-Pearson DL, Soper JT, Montana GS: Transperineal templates for brachytherapy treatment of pelvic malignancies: A comparison of standard and customized templates. Biol Phys 19:751, 1990.
65. Soisson AP, Soper JT, Clarke-Pearson DL, Berchuck A, Montana GS, Creasman WT: Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol 37:390, 1990.
66. Olt GJ, Greenberg C, Synan IS, Coleman RE, Clarke-Pearson DL: Preoperative assessment of fragment D-Dimer as a predictor of postoperative venous thrombosis. Am J Obstet Gynecol 162:772-775, 1990.
67. Mutch DG, Soper JT, Babcock CJ, Christensen CW, Clarke-Pearson DL, Hammond CB: Recurrent gestational trophoblastic disease: Experience of the Southeastern Trophoblastic Disease Center. Cancer 66:978, 1990.
68. Clarke-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE: A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 75:684-689, 1990.
69. Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC Jr: Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 162:883-888, 1990.
70. Soisson AP, Geszler J, Soper JT, Berchuck A, Clarke-Pearson DL: A comparison of symptomatology, physical examination, and vaginal cytology in detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 76:106, 1990.
71. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast JC Jr.: Preoperative evaluation of serum CA-125, TAG-72, and CA-15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163:1204-1209, 1990.
72. Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr: The prognostic significance of CA-125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163:1164-1167, 1990.
73. Kohler MF, Berchuck A, Baker ME, Szpak CA, Soper JT, Clarke-Pearson DL: Computed tomography guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology. Obstet Gynecol 76:612-616, 1990.
74. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr: Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 76:381-387, 1990.
75. Shpall EJ, Clarke-Pearson DL, Soper JT, Berchuck A, Jones RB, Bast RC Jr., Ross M, Lidor Y, Vanacek K, Tyler T, Peters WP: High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386-391, 1990.
76. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-91, 1990.
77. Cliby W, Soisson AP, Berchuck A, Clarke-Pearson DL: Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy. Cancer 67:2415-2417, 1991.
78. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr: Increased serum levels of macrophage colony stimulating factor in ovarian cancer. Am J Obstet Gynecol 165:1356-1362, 1991.
79. Soper JT, Clarke-Pearson DL, Berchuck A: The clinical significance of blood transfusion at the time of radical hysterectomy. (Letter). Obstet Gynecol 77:165, 1991.
80. Kohler MF, Soper JT, Tucker JA, Clarke-Pearson DL: Isolated incisional metastases after intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma. Cancer 68:1380-83, 1991.
81. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164:745-50, 1991.
82. Marks JR, Davidoff AM, Kerns BJ, Pence J, Dodge RK, Humphrey PA, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-84, 1991.
83. Soper JT, Couchman G, Berchuck A, Clarke-Pearson DL. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 41:239-44, 1991.
84. Soper JT, Berchuck A, Clarke-Pearson DL: Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. Cancer 68:725-729, 1991.
85. Berchuck A, Rodriguez GC, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC Jr: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15-21, 1991.
86. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164:669-674, 1991.
87. Stellar MA, Soper JT, Szpak CA, Lanman JT, Clarke-Pearson DL: The importance of determining karyotype in premenarchal females with gonadal dysgerminoma: Two case reports. Int J Gynecol Cancer 1:141, 1991.
88. Livengood CH, Soper JT, Clarke-Pearson DL, Addison WA: Necrotizing fasciitis in irradiated tissues of diabetic patients. J Reprod Med 36:455-458, 1991.
89. Massad LS, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman WT: Epithelial ovarian tumors of low malignant potential. Obstet Gynecol 78(6):1027-1032, 1991.
90. Slayton RE, Blessing JA, Clarke-Pearson DL: A phase II clinical trial of Diaziquone (AZQ) In the treatment of patients with recurrent mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group Study. (Brief Report) Investigational New Drugs 9:93-94, 1991.
91. O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George SL, Berchuck A, Soper J, Fowler W, Clarke-Pearson DL, Bast RC: Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol 45:299, 1992.
92. Berchuck A, Rodriguez G, Olt GJ, Boente MP, Whitaker R, Arrick B, Clarke-Pearson DL, Bast RC Jr: Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 166(2):676-84, 1992.
93. Berchuck A, Boente MP, Soper JT, Kerns BJ, Kinney RJ, Clarke-Pearson DL, Bacus SS, Bast RC Jr: Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 44:61-65, 1992.
94. Montana GS, Anscher MS, Mansbach CM, Daly N, Delannes M, Clarke-Pearson DL, Gaydica EF: Topical application of WR-2721 to prevent radiation proctosigmoiditis. A phase I/II trial. Cancer 69:2826-2830, 1992.
95. Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL: Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Obstet Gynecol 79:993-7, 1992.
96. Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL: Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol 10:1553-1560, 1992.
97. Olt G, Berchuck A, Soisson AP, Boyer C, Bast RC, Clarke-Pearson DL: Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 70:2137-42, 1992.
98. Nicholaides AN, Areelus J, Belcaro G, Bergqvist D, Borris LC, Buller HR, Caprini JA, Christopoulos D, Clarke-Pearson D, et al: Prevention of venous thromboembolism: European consensus statement. Int Angiology II:151-159, 1992.
99. Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL: Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 80(6):949-952, 1992.
100. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC Jr: The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Amer J Obstet Gynecol 167:1877-1882, 1992.
101. Soisson AP, Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL: Radical hysterectomy in obese women. Obstet Gynecol 80:940, 1992.
102. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr., Marks JR: Overexpression and mutation of p53 in endometrial cancer. Cancer Res 52:1622-27, 1992.
103. Boente MP, Berchuck A, Whitaker RS, Kalen A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC Jr.: Antibodies against immunochemically distinct epitopes on the extracellular domain of HER-2/neu c-cerbB-2 inhibit growth of breast and ovarian cancer cell lines. Int J Cancer 53:401-408, 1993.
104. Asbury RF, Blessing JA, Look KY, Clarke-Pearson DL, Homesley HD: A Gynecologic Oncology Group phase II study of AMONAFIDE in epithelial ovarian cancer. Am J Clin Oncol 16(6):529-531, 1993.
105. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE: A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 168:1146-54, 1993.
106. Xu FJ, Yu Y, Daley C, DeSombre K, Hass M, Anselmino L, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, Layfield LJ, Bast RC: The OVX1 radioimmunoassay complements CA125 for predicting the presence of residual ovarian carcinoma at second look surgical surveillance procedures. J Clin Oncol, 11:1506-1510, 1993.
107. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519, 1993.
108. Leopold KA, Oleson JR, Clarke-Pearson DL, Soper JT, Berchuck A, Samulski T, Page
RL, Bliven J, Dewhirst M: Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys 27:1245, 1993.
109. Kohler MF, Nishii H, Humphrey PA, Sasaki H, Boyd JA, Marks J, Bast RC, Clarke-Pearson DL, Berchuck A.: Mutation of the p53 tumor supressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 169:690-4, 1993.
110. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr: Elevation of multiple serum markers in patients with Stage I ovarian cancer. J Nat Can Inst 85:1748-1751, 1993.
111. Woolas R, Xu FJ, Daly L, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL, Boyer CM, Bast RC Jr: Screening strategies for ovarian cancer. Diag Oncol 3:287-293, 1993.
112. Clarke-Pearson, DL: Reassessment of ovarian cancer: What are our goals? Gynecol Oncol 52:151-153, 1994.
113. Soper JT, Evans AC, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB: Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 83(1):113-117, 1994.
114. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC: Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52:232-236, 1994.
115. Myers ER, Clarke-Pearson DL, Olt GJ, Soper JT, Berchuck A: Preoperative coagulation testing on a gynecologic oncology service. Obstet Gynecol 83:438-444, 1994.
116. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK: The negative prognostic implications of thrombocytosis in women with Stage IB cervical cancer. Obstet Gynecol 83:445-448, 1994.
117. Ben-Haim S, Kahn D, Weiner GJ, Madsen MT, Waxman AD, Williams CM, Clarke-Pearson DL, Coleman ER, Maguire RT: The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379). Nucl Med Biol 21(2):131-142, 1994.
118. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB: 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic Disease. Gynecol Oncol 54:76-79, 1994.
119. Lukes A, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke- Pearson DL, Bast RC Jr., Berchuck A: Multivariate analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 79:2380-85, 1994.
120. Soisson AP, Olt G, Soper JT, Berchuck A, Rodriguez GC, Clarke-Pearson DL: Prevention of superficial wound separation with subcutaneous retention sutures. Gynecol Oncol 51:330-4, 1994.
121. Xu FJ, Yu YH, Daley L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis MS, Boyer C, Bast RC Jr.: OVX1 as a marker for early stage endometrial carcinoma. Cancer 73(7):1855-1858, 1994.
122. Soper JT, Evans AC, Conaway MR, Clarke-Pearson DL, Berchuck A, Hammond CB: Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Gest Tropho Tumor 84(6):969-973, 1994.
123. Rodriguez GC, Hughes CL, Soper JT, Berchuck A, Clarke-Pearson DL, Hammond CB: Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia. Obstet Gynecol 84:794-7, 1994.
124. Soper JT, Evans AC, Rodriguez G, Berchuck A, Clarke-Pearson DL, Hammond CB: Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol 56:421-424, 1995.
125. Berchuck A, Anspach C, Evans AC, Soper JT, Rodriguez GC, Dodge R, Robboy S, Clarke-Pearson DL: Post-surgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gyn Onc 59:20-24, 1995.
126. Woolas RP, Conaway MR, Xu FJ, Jacobs IJ, Yu YJ, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson D, Rodriguez G, Oram DH, Bast RC Jr: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-6, 1995.
127. Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affronti ML, Jones RB, Shpall EJ, Rubin P, Elkordky M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Pearson D, Berry DA, Peters WA: A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral blood progenitor cells in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology 37:561-568, 1995.
128. Evans AC, Clarke-Pearson DL, Rodriguez GC, Berchuck A, Hammond CB: Gestational Trophoblastic Disease metastatic to the central nervous system. Gyn Oncol 59:226-230, 1995.
129. Clarke-Pearson DL: Crafting the operative note: techniques critical to success (editorial). J Gynecol Tech 1(3):119-120, 1995.
130. Liu JR, Conaway M, Rodriguez GC, Soper JT, Clarke-Pearson DL, Berchuck A: Poor prognosis of black women with endometrial cancer is not due to delayed treatment. Obstet Gynecol 86:486-90, 1995.
131. LoCoco S, Covens A, Carney M, Franssen E, Dodge R, Rosen B, Osborne B, Kerr I, Buckman R, Soper J, Ridriguez G, DePetrillo A, Clarke-Pearson D, Berchuck A: Does aggressive therapy improve survival in suboptimal stage IIIC/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 59:194-9, 1995.
132. Soper JT, Rodriguez G, Berchuck A, Clarke-Pearson DL: Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: Comparison of flap-specific complications. Gynecol Oncol 56:271, 1995.
133. Weber TM, Sostman HD, Spritzer CE, Ballard RL, Meyer GA, Clarke-Pearson DL, Soper JT: Cervical carcinoma: Determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology 194:135-139, 1995.
134. Hurteau JA, Rodriguez G, Berchuck A, Soper JT, Cliby W, Soisson AP, Clarke-Pearson, DL: Closed retroperitoneal suction drainage compared to no drainage in patients having undergone selective lymphadenectomy: Risks and benefits. J Gynecol Tech (1) 4:195-199, 1995.
135. Clarke-Pearson DL: Prevention of venous thrombosis following gynecologic Surgery. J Gynecol Tech 1(1):11-17, 1995.
136 Moore DH, Valea F, Walton LA, Soper JT, Clarke-Pearson DL, Fowler WC, Jr.: A phase I study of intraperitoneal-alpha2b interferon and intravenous cisplatin plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: A Gynecologic Oncology Group pilot study. Gynecol Oncol 59:267-272, 1995.
136. Hurteau JA, Rodriguez GC, Kay HH, Bentley RC, Clarke-Pearson DL: Villoglandular adenocarcinoma of the cervix: A case report. Obstet Gynecol 85:906-908, 1995.
138. Cliby WA, Clarke-Pearson DL, Dodge R, Kohler ME, Rodriguez GC, Olt GJ, Soper JT, Berchuck A, Soisson AP: Acute morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma. J Gynecol Tech 1:19-25, 1995.
138. Massad LS, Bitterman P, Clarke-Pearson DL: Case Report: Metastatic clear cell eccrine hidradenocarcinoma of the vulva: Survival after primary surgical resection. Gynecol Oncol 61:287-290, 1996.
139. Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC Jr: Preoperative evaluation of macrophage colony stimulating factor levels (M-CSF) in patients with endometrial cancer. Am J Obstet Gynecol 174:1316-19, 1996.
140. Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD, Zaino RJ: An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Oncol 63(3):304-311, 1996.
141. Stehman FB, Bundy BN, Harrison B, Clarke-Pearson DL: Sites of failure and times to failure in carcinoma of the vulva treated conservatively: A Gynecologic Oncology Group study. Am J Obstet Gynecol 174 (4):1128-33, 1996.
142. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A: p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175:1246-52, 1996.
143. Alberts DS, Liu PY, Hannigan EV, O=Toole R, William SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ: Intraperitoneal Cisplatin plus intravenous Cyclophosphamide versus intravenous Cisplatin plus intravenous Cyclophosphamide in stage III ovarian cancer. N Engl J Med 335:1950-55, 1996.
144. McGuire WP, Hoskins WJ, Brady M, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: A phase III randomized study of Cyclophosphamide and Cisplatin versus Paclitaxel and Cisplatin in patients with suboptimal stage III and IV epithelial ovarian cancer. N Engl J Med 334:1-6, 1996.
145. Rodrigeuz GC, Soper JT, Ho M, Dodge R, Berchuck A, Clarke-Pearson DL: A comparison of interrupted versus continuous Smead-Jones abdominal closure. J Gynecol Tech 2:19-23, 1996.
146. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch D, Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol (Dibromodulcitol) versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 15:165-171, 1997.
147. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group Study. Semin Oncol 24 (1 Suppl 2):S2-13-S2-16, 1997.
148. Hoskins WJ, McGuire WP, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Combination paclitaxel (Taxol) - cisplatin vs cyclophosphamide -cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer. Supplement: Int J Gynecol Cancer 7:9-13, 1997.
149. Roberts JA, Jenison EL, Clarke-Pearson D, Longleben A: A randomized, multicenter, double-blind, placebo-controlled, dose finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172-177, 1997.
150. Clifford SL, Kaminetsky CP, Cirisano FD, Dodge R, Soper JT, Clarke-Pearson DL, Berchuck A: Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol 176:S229-32, 1997.
151. Woolas RP, Jacobs IJ, XU F, Berchuck A, Soper JT, Clarke-Pearson DL, Spence-Jones
S, Oram D, Hudson CN, Shepherd JH, Bast RC, Jr.: Multiple tumor marker measurements to differentiate stage I ovarian cancer from the benign ovarian cyst. Gyn Techniques Vol (3) 3:123-126, 1997.
152. Boente MP, Berchuck A, Whitaker RS, Kalen A, Xu FJ, Clarke-Pearson DL, Bell RM,
Bast RC: Suppression of Diacylglycerol Levels by Antibodies Reactive with c-erbB-2 (HER-2/neu) Gene Product p185c-erbB-2 in Breast and Ovarian Cancer Cell Lines. Gynecol Oncol 70:49-55, 1998.
153. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Clarke-Pearson DL, Liao SY: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 17:1339-48, 1999.
154. Cirisano FE Jr. Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74:385-94, 1999.
155. Ashih H. Gustilo-Ashby T, Myers ER, Andrews J, Clarke-Pearson DL,, Berry D, Berchuck A. Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol 74:208-16, 1999.
156. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144-53, 1999.
157. Maxwell GL, Myers ER, Clarke-Pearson DL. Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstetrics & Gynecol 95:206-14, 2000.
158. Cirisano FD Jr., Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77:55-65, 2000.
159. Rader J, Clarke-Pearson, Moore M, et al. Phase II Trial of ZD9331 as third-line therapy for patients with ovarian carcinoma. Ann Oncol 2000; 11 (4): 83
160. Clarke-Pearson DL, Van Le L, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ. Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer. J Clin Oncol 2001; 19: 3976-3975
161. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Prevention of Venous Thrombosis in Postoperative Gynecologic Oncology Patients: A Prospective Randomized Trial Comparing Pneumatic Calf Compression and Low Molecular Weight Heparin (dalteparin) Obstet Gynecol 2001; 98: 989-995
162. Maxwell GL, Synan I, Hayes R, Clarke-Pearson DL. Preference and Compliance in Thromboembolism Prophylaxis for Gynecologic Oncology Patients. Obstet Gynecol. 2002, 100: 451
163. Markman M, Bundy B, Alberts D, Fowler J, Clarke-Pearson D, Carson LF, Walder S, Sickel J. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian cancer: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol; 2001; 19: 1001-1007
164. Bookman MA, Darcy KM, Clarke-Pearson DL, Boothby R, Horwitz I. Evaluation of monoclonal Humanoized Anti-HER2 Antibody (Trastuzumab, Herceptin) in Patients with recurrent or refractory Ovarian or Primary Peritoneal Carcinoma with Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
165. Clarke-Pearson DL, Maxwell GL, Synan I, Dodge R, McClelland C. Risk factors which predispose patients to thromboembolism despite prophylaxis with external pneumatic compression. Obstet Gynecol 2003; 101:157-163.
166. Gore M, Oza A, Rustin G, Malefetano J, Calvert H, Clarke-Pearson D, Carmichael J, Ross G, Beckman R, Fields S. A Randomized Trial of Oral versus Intravenous Topotecan in Patients with relapsed epithelial Ovarian Cancer. Euro J Cancer. 2002; 38:57-63.
167. Bloss JD, Brady M, Rocereto T, Partridge EE, Clarke-Pearson DL. Extraovarian Peritoneal Serous Papillary Carcinoma: A Phase II Trial of Cisplatin and Cyclophosphamide with Comparison to a cohort with Papillary Serous Ovarian Carcinoma-A Gynecologic Oncology Group Study. Gynecol Oncol 2003; 89:148-54
168. Rader JS, Clarke-Pearson DL, Moore M, Carson L, Holloway R, Kao M-S, Witnitzer I, Douglass EC. A Phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pre-treated patients with ovarian cancer. Gynecol Oncol(accepted)
169. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal Radioactive Phosphorous (32P) versus observation folowing negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 2849-2855
170. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson DL, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen R. Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
171. Soper JT, Reisinger SA, Asbury R, Jones E, Clarke-Pearson DL. Feasibility Study of Concurrent Weekly Cisplatin and Whole Abdominopelvic Irradiation Followed by Doxorubicin/Cisplatin Chemothereapy for Locally Advanced Endometrial Carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2004; 95: 95-100.
172. Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME: Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003; 88: 51-57.
173. Roth TM, Secord AA, Havrilesky LJ, Jones E, Clarke-Pearson DL . High Dose Rate Intraoperative Radiotherapy for Recurrent Cervical Cancer and Nodal Disease. Gynecol Oncol. 2003; 91: 258-260.
174. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90: 186-190
175. Havrilesky LJ, Peterson BL, Dryden DK, Soper JT, Clarke-Pearson DL, Berchuck A. Predictors of clinical Outcomes in the Laparoscopic Management of Adenxal Masses. Obstet Gynecol. 2003; 102: 243-51
176. Alvarez A, Clarke-Pearson DL. Platinum-Resistant and Refractory Ovarian Cancer: Second-Line Treatment Options. Am J Cancer 2003; 2: 1-13.
177. Jones EL, Samulski TV, Dewhirst MW, Secord AA, Berchuck A, Clarke-Pearson DL, Havrilesky LJ, Soper J, Prosnitz LR. A Pilot Phase II Trial of Concurrent Radiotherapy, Chemotherapy, and Hyperthermia for Locally Advanced Cervical Carcinoma. Cancer. 2003; 98:277-282.
178. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. Secondary Surgical Cytoreduction for Advanced Stage Ovarian Carcinoma with Suboptimal Residual Disease. N Engl J Med. 2004; 351: 2489-97.
179. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003; 91: 318-25
180. Dainty L, Maxwell GL, Clarke-Pearson DL, Myers ER. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. Gynecol Oncol 2004; 93: 366-73.
181. Secord AA, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia 2005; 21: 333-47
182. Spriggs D, Brady M, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. A Phase III Randomized Trial of IV Cisplatin plus Paclitaxel as a 24- or 96-Hour Infusion in Patients with Selected Stage III or Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. (Submitted Am J Clin Oncol) 2004
183. Greer B, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson DL, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected Stage III Ovarian Cancer: A non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 99: 71-9.
184. Walker JL, Armstrong D, Huang H, Fowler J, Webster K, Burger R, Clarke-Pearson D. Intraperitoneal Catheter Outcomes in a Phase III Trial of Intravenous vs. Intraperitoneal Chemotherapy in Optimal Stage III Ovarian and Primary Peritoneal Cancer. A Gynecologic Oncology Group Study. Gynecol Oncol 2005; 100: 27-32.
185. Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005; 99: 689-95.
186. Soper JT, Havrilesky LJ, Secord AA, Berchuck A, Clarke-Pearson DL. Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery. Int J Gynecol Cancer. 2005; 15: 542-8.
187. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005; 23: 3668-75.
188. Soper JT, Secord AA, Havrilesky LJ, Berchuck A, Clarke-Pearson DL. Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison fo flap-relatred morbidity. Gynecol Oncol. 2005; 97: 596-601.
189. Lutman CV, Havrilesky LJ, Cragun JM, Secord A, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is an important prognostic variable for FIGO Stage I and II endometrial carcinoma with high risk histology. Gynecol Oncol (accepted 2006)
E-mail: danielcp@email.unc.edu
Telephone: (919) 966-5281
FAX: (919) 966-6049
Address: 5003 Old Clinic Chapel Hill, NC 27599
